This article was originally published in Start Up
Executive SummaryWhile there, he found that when human bone marrow cells were treated in a unique way and implanted into an animal brain, the treated cells migrated throughout the brain and differentiated into human neurons. He also found that when these treated cells were implanted into a rodent eye with a damaged retina, the cells migrated to the area of damage and differentiated into new photoreceptor cells. Another discovery by Sugaya identified a small molecule that significantly increased the number of stem cells in the hippocampus and cortex of aged rats.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.